Applied Therapeutics Reports Third Quarter 2020 Financial Results
Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)
On track to initiate rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG studies in the first half of 2021
Continued collaboration with FDA to restart the ACTION-Galactosemia Kids pediatric study
“In the third quarter we continued to execute on our Diabetic Cardiomyopathy program, with strong enrollment in our ARISE-HF global Phase 3 registrational study, and new data presented on AT-001 mechanism of action and improvement in cardiac energetics,” said
- Shared data on AT-001 at the
American Heart Associationscientific sessions demonstrating that AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM).
- Executed a licensing and research collaboration agreement with the
University of Miamion SORD Deficiency (genetically identified by the Miamiclinical team in a May 2020Nature publication). SORD Deficiency is a debilitating hereditary neuropathy affecting over 3,000 patients in the US.
- The pediatric Galactosemia clinical study (ACTION-Galactosemia kids) remains on partial clinical hold as the Company continues to work collaboratively with FDA to restart the study. The rationale for partial hold is not safety related, and the issues being addressed relate to design and operational aspects of the trial. The Company plans to submit an NDA no later than Q3 2021.
- Presented Data on AT-007 for the Treatment of Galactosemia at the
American Society of Human Genetics(ASHG) 2020 Annual Meeting. In October 2020, we presented two poster presentations covering AT-007 in Galactosemia at the ASHG 2020 Annual Meeting. The presentations included animal model efficacy data and adult clinical data on the safety and biomarker efficacy of AT-007.
- Announced Pediatric Rare Disease Designation and Orphan Drug Designation for AT-007 for the treatment of PMM2-CDG. PMM2-CDG is a debilitating rare disease caused by deficiency in the critical enzyme phosphomannomutase-2, required for systemic glycosylation of proteins. PMM2-CDG causes multiple organ failure and severe disability, resulting in approximately 20% mortality in the first four years of life. There are currently no drugs approved to treat PMM2-CDG.
- Presented Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the
European Association for the Study of Diabetes(EASD). In September 2020, we presented two poster presentations covering AT-001, a next generation aldose reductase inhibitor (ARI), in Phase 3 development for Diabetic Cardiomyopathy at the 56th Annual EASD Meeting. The presentations included data on the safety and specificity of AT-001, as well as data on mechanistic protection from cellular damage during hyperglycemia.
- Cash and cash equivalents and short-term investments totaled
$116.5 millionas of September 30, 2020, compared with $38.9 millionat December 31, 2019.
- Research and development expenses for the three months ended
September 30, 2020were $19.9 million, compared to $7.5 millionfor the three months ended September 30, 2019. For the three months ended September 30, 2020, the increase of $12.5 millionwas primarily due to an increase in clinical and pre-clinical expense of $4.6 million, primarily related to the progression of the AT-007 ACTION-Galactosemia adult extension study, the AT-007 ACTION-Galactosemia Kids pediatric registrational study and the AT-001 Phase 3 ARISE-HF clinical study; an increase in drug manufacturing and formulation costs of $7.2 millionprimarily related to raw material deliveries in support of the 2020 manufacturing campaigns and the completion and release of AT-001 and AT-007 drug product batches; an increase in personnel expenses of $0.2 milliondue to the increase in headcount in support of our clinical program pipeline; an increase in stock-based compensation of $0.1 milliondue to new stock option and restricted stock unit grants during the three months ended September 30, 2020; and an increase in regulatory and other expenses of $0.4 millionrelating to an increase in clinical consulting fees during the three months ended September 30, 2020.
- General and administrative expenses were
$10.0 millionfor the three months ended September 30, 2020, compared to $3.3 millionfor the three months ended September 30, 2019. For the three months ended September 30, 2020, the increase of $6.7 millionwas primarily related to the increase in personnel expenses of $1.2 millionand an increase in stock-based compensation of $1.0 milliondue to the increase in headcount, $1.0 millionrelated to an increase in legal and professional fees due to increased operations and costs associated with being a public company, $2.4 millionrelated to the establishment of a commercial department, $0.2 millionrelated to increased insurance costs, and $0.9 millionin other expenses relating to increased costs of rent and other office expenses.
- Net loss for the third quarter of 2020 was
$29.8 million, or $1.33per basic and diluted common share, compared to a net loss of $10.7 million, or $0.63per basic and diluted common share, for the third quarter 2019.
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the timing of our NDA submission for potential approval of AT-007, which will include data from the ACTION-Galactosemia Kids trial and the 90-day safety data in adults with Galactosemia, (ii) the design, scope and results of our clinical trials, (iii) the timing of the initiation and completion of our clinical trials, (iv) the likelihood that data from our clinical trials will support future development of our product candidates, and (v) the likelihood of obtaining regulatory approval of our product candidates and qualifying for any special designations, such as orphan drug designation. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, (i) our plans to develop and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates on reasonable terms, (vi) our ability to maintain and establish collaborations or obtain additional funding, (vii) our ability to obtain regulatory approval of our current and future product candidates, (viii) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (ix) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, (x) the implementation of our business model and strategic plans for our business and product candidates, (xi) our intellectual property position and the duration of our patent rights, (xii) developments or disputes concerning our intellectual property or other proprietary rights, (xiii) our expectations regarding government and third-party payor coverage and reimbursement, (xiv) our ability to compete in the markets we serve, (xv) the impact of government laws and regulations and liabilities thereunder, (xvi) developments relating to our competitors and our industry, (xvii) the impact of the COVID-19 pandemic on the timing and progress of our ongoing clinical trials and our business in general and (xviii) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the
(212) 600-1902 or
Statement of Operations
(in thousands, except share and per share data)
|Three Months Ended||Nine Months Ended|
|Research and development||$||19,945||$||7,453||$||47,974||$||18,582|
|General and administrative||10,020||3,294||22,744||9,331|
|Total operating expenses||29,965||10,747||70,718||27,913|
|LOSS FROM OPERATIONS||(29,965||)||(10,747||)||(70,718||)||(27,913||)|
|OTHER INCOME (EXPENSE), NET:|
|Interest income (expense), net||131||34||435||33|
|Other income (expense)||(10||)||—||11||—|
|Total other income (expense), net||121||34||446||33|
|Net loss attributable to common stockholders—basic and diluted||$||(29,844||)||$||(10,713||)||$||(70,272||)||$||(27,880||)|
|Net loss per share attributable to common stockholders—basic and diluted||$||(1.33||)||$||(0.63||)||$||(3.22||)||$||(1.98||)|
|Weighted-average common stock outstanding—basic and diluted||22,426,203||17,095,870||21,790,207||14,085,579|
(in thousands, except share and per share data)
|As of||As of|
|Cash and cash equivalents||$||48,679||$||18,850|
|Prepaid expenses and other current assets||6,380||7,301|
|Total current assets||122,885||46,155|
|Operating lease right-of-use asset||1,754||2,035|
|Security deposits and leasehold improvements||199||199|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Current portion of operating lease liabilities||380||356|
|Accrued expenses and other current liabilities||18,177||4,950|
|Total current liabilities||20,502||14,099|
|Noncurrent portion of operating lease liabilities||1,396||1,683|
|Total noncurrent liabilities||1,396||1,683|
|Additional paid-in capital||240,074||99,378|
|Accumulated other comprehensive loss||(94||)||(2||)|
|Total stockholders' equity||102,940||32,607|
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||124,838||$||48,389|
Source: Applied Therapeutics